Health & Fitness
Thu, February 12, 2009Wed, February 11, 2009Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009StemCells, Inc. to Present at the 11th Annual BIO CEO & Investor Conference
//health-fitness.news-articles.net/content/2009/ .. the-11th-annual-bio-ceo-investor-conference.html
Published in Health and Fitness on Thursday, February 5th 2009 at 4:56 GMT, Last Modified on 2009-02-05 04:56:49 by Market WirePALO ALTO, Calif.--([ BUSINESS WIRE ])--StemCells, Inc. (NASDAQ:STEM) today announced that Martin McGlynn, the Company's President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference which is being held February 9-10, 2009 at the Waldorf-Astoria in New York. Mr. McGlynn, who is scheduled to speak on Monday, February 9th at 9:00 a.m., Eastern Standard Time, plans to report on the status of the Company's CNS and Liver Programs, including its Phase I clinical trial in neuronal ceroid lipofuscinosis and its recently approved IND (Investigational New Drug application) for a clinical trial in Pelizeaus-Merzbacher Disease.
A webcast of the presentation will be available through [ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=86230&eventID=2079621 ] or on the Company's web site [ www.stemcellsinc.com ] (under the "Investors" tab). The presentation will remain accessible until March 9, 2009.
About StemCells, Inc.
StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The Company's product development programs seek to repair or repopulate CNS and liver tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of HuCNS-SC® cells, its highly purified, expandable population of human neural stem cells. StemCells owns or has exclusive rights to more than 50 issued or allowed U.S. patents and more than 150 granted or allowed non-U.S. patents. Further information about the Company is available on its web site at: [ www.stemcellsinc.com ]
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (the "Company") and its ability to conduct clinical trials as well as its research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. Please refer to "Risk Factors" in Item 1A of Part II of the Company's Quarterly Report on Form 10-Q for risks and other factors that may affect the Company's business operations.
